Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Vaccine
    September 2021
  1. ANGSUWATCHARAKON P, Puthanakit T, Bunjoungmanee P, Anugulruengkitt S, et al
    High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
    Vaccine. 2021 Sep 20. pii: S0264-410X(21)01127.
    >> Share

  2. ABREU E SILVA HB, Correa HP, Ribeiro IA, Nascimento VAM, et al
    Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil.
    Vaccine. 2021 Sep 7. pii: S0264-410X(21)01009.
    >> Share

    August 2021
  3. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share

  4. HAGAN LM, Dusseau C, Crockett M, Rodriguez T, et al
    COVID-19 vaccination in the Federal Bureau of Prisons, December 2020-April 2021.
    Vaccine. 2021 Aug 14. pii: S0264-410X(21)01078.
    >> Share

  5. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021 Aug 13. pii: S0264-410X(21)01035.
    >> Share

  6. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    >> Share

    July 2021
  7. HUANG Y, Seaton KE, Casapia M, Polakowski L, et al
    AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
    Vaccine. 2021 Jul 3. pii: S0264-410X(21)00827.
    >> Share

    June 2021
  8. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    >> Share

  9. MESHER D, Thomas SL, Linley E, Edmundson C, et al
    Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00580.
    >> Share

  10. CHUA JV, Davis C, Husson JS, Nelson A, et al
    Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00685.
    >> Share

  11. WOLFE LS, Smedley JG 3rd, Bubna N, Hussain A, et al
    Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00668.
    >> Share

    May 2021
  12. GREWAL R, Deeks SL, Hart TA, Cox J, et al
    Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00603.
    >> Share

  13. BENDER MF, Li Y, Ivleva VB, Gowetski DB, et al
    Protein and glycan molecular weight determination of highly glycosylated HIV-1 envelope trimers by HPSEC-MALS.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00634.
    >> Share

  14. GULLA K, Cibelli N, Cooper JW, Fuller HC, et al
    A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00545.
    >> Share

    April 2021
  15. XIRIDOU M, Visser M, Urbanus A, Matser A, et al
    Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00433.
    >> Share

  16. DANIEL M, Liang B, Luo M
    Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00372.
    >> Share

    March 2021
  17. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    >> Share

  18. GOBERT C, Van Hauwermeiren C, Quoidbach C, Reschner A, et al
    Tetanus seroprotection in people living with HIV: Risk factors for seronegativity, evaluation of medical history and a rapid dipstick test.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00242.
    >> Share

    January 2021
  19. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    >> Share

  20. MUGO N, Eckert LO, Odero L, Gakuo S, et al
    Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31587.
    >> Share

  21. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    >> Share

  22. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    >> Share

    December 2020
  23. KOSKAN A, Klasko-Foster L, Stecher C, Rodriguez S, et al
    Human papillomavirus vaccine guideline adherence among Arizona's Medicaid beneficiaries.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31609.
    >> Share

  24. DOUGLASS N, van Diepen MT, Chapman R, Galant S, et al
    Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity.
    Vaccine. 2020 Dec 17. pii: S0264-410X(20)31591.
    >> Share

    November 2020
  25. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    >> Share

  26. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    >> Share

    October 2020
  27. MANGION M, Gelinas JF, Bakhshi Zadeh Gashti A, Azizi H, et al
    Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31367.
    >> Share

  28. CHESSON HW, Meites E, Ekwueme DU, Saraiya M, et al
    Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Vaccine. 2020 Oct 26. pii: S0264-410X(20)31312.
    >> Share

  29. MALTEZOU HC, Theodoridou K, Tseroni M, Raftopoulos V, et al
    Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January-March 2020.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31276.
    >> Share

  30. MCCLUNG N, Burnett J, Wejnert C, Markowitz LE, et al
    Human papillomavirus vaccination coverage among men who have sex with men-National HIV Behavioral Surveillance, United States, 2017.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31081.
    >> Share

  31. YAO L, Wang JY, Bao LN, Fan MX, et al
    DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31259.
    >> Share

    September 2020
  32. TEMPIA S, Moyes J, Cohen AL, Walaza S, et al
    Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31193.
    >> Share

    August 2020
  33. GALILI U
    Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31073.
    >> Share

    July 2020
  34. CURLIN ME, Shao J, Diaz G, Edlefsen PT, et al
    Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine.
    Vaccine. 2020 Jul 14. pii: S0264-410X(20)30829.
    >> Share

    June 2020
  35. PARIZE P, Poujol P, Morineau Le Houssine P, Goesch J, et al
    Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30823.
    >> Share

  36. SAADE E, Gravenstein S, Donskey CJ, Wilson B, et al
    Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections.
    Vaccine. 2020 Jun 16. pii: S0264-410X(20)30797.
    >> Share

  37. MOSITES E, Seeman S, Negus S, Homan C, et al
    Immunogenicity of the hepatitis A vaccine 20 years after infant immunization.
    Vaccine. 2020 Jun 10. pii: S0264-410X(20)30724.
    >> Share

    May 2020
  38. POWELL AM, Luo Z, Martin L, Wan Z, et al
    Corrigendum to "The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals
    Vaccine. 2020 May 27. pii: S0264-410X(20)30673.
    >> Share

  39. YANG GJ, Yang Y, Shaddeau A, Cai CX, et al
    A unique algorithm for the determination of peptide-carrier protein conjugation ratio by amino acid analysis using intrinsic internal standard.
    Vaccine. 2020 May 21. pii: S0264-410X(20)30642.
    >> Share

  40. SILVERBERG MJ, Leyden WA, Lam JO, Chao CR, et al
    Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women.
    Vaccine. 2020 May 20. pii: S0264-410X(20)30610.
    >> Share

  41. TEMPIA S, Walaza S, Moyes J, McMorrow ML, et al
    Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30539.
    >> Share

  42. PALLIKKUTH S, Bolivar H, Fletcher MA, Babic DZ, et al
    A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy.
    Vaccine. 2020 May 6. pii: S0264-410X(20)30485.
    >> Share

  43. MACDONALD N, Mohsni E, Al-Mazrou Y, Kim Andrus J, et al
    Global vaccine action plan lessons learned I: Recommendations for the next decade.
    Vaccine. 2020 May 5. pii: S0264-410X(20)30609.
    >> Share

    April 2020
  44. LEE JH, Hong S, Im JH, Lee JS, et al
    Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients.
    Vaccine. 2020 Apr 22. pii: S0264-410X(20)30492.
    >> Share

  45. MUTSAERTS EAML, Nunes MC, Bhikha S, Ikulinda BT, et al
    Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.
    Vaccine. 2020 Apr 16. pii: S0264-410X(20)30433.
    >> Share

  46. GARY E, O'Connor M, Chakhtoura M, Tardif V, et al
    Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.
    Vaccine. 2020 Apr 9. pii: S0264-410X(20)30436.
    >> Share

  47. CHEBLOUNE Y, Moussa M, Arrode-Bruses G, Ronfort C, et al
    A single lentivector DNA based immunization contains a late heterologous SIVmac251 mucosal challenge infection.
    Vaccine. 2020 Apr 8. pii: S0264-410X(20)30442.
    >> Share

    March 2020
  48. WOESTENBERG PJ, van Benthem BHB, Bogaards JA, King AJ, et al
    HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.
    Vaccine. 2020 Mar 19. pii: S0264-410X(20)30330.
    >> Share

  49. LAI JI, Eszterhas SK, Brooks SA, Guo C, et al
    Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity.
    Vaccine. 2020 Mar 16. pii: S0264-410X(20)30354.
    >> Share

  50. MCCLYMONT E, Ogilvie G, Albert A, Johnston A, et al
    Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.
    Vaccine. 2020 Mar 5. pii: S0264-410X(20)30319.
    >> Share

    February 2020
  51. SHU J, Shen W, Liu H, Zhou Y, et al
    The immunologic dominance of an epitope within a rationally designed poly-epitope vaccine is influenced by multiple factors.
    Vaccine. 2020 Feb 29. pii: S0264-410X(20)30298.
    >> Share

  52. CHURCH JA, Chasekwa B, Rukobo S, Govha M, et al
    Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants.
    Vaccine. 2020 Feb 19. pii: S0264-410X(20)30150.
    >> Share

  53. ZHOU Y, Lin YF, Meng X, Duan Q, et al
    Anal human papillomavirus among men who have sex with men in three metropolitan cities in southern China: implications for HPV vaccination.
    Vaccine. 2020 Feb 19. pii: S0264-410X(20)30176.
    >> Share

  54. MADHI SA, Izu A, Violari A, Cotton MF, et al
    Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30223.
    >> Share

  55. OVERTON ET, Lawrence SJ, Stapleton JT, Weidenthaler H, et al
    A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS.
    Vaccine. 2020 Feb 11. pii: S0264-410X(20)30085.
    >> Share

  56. GARY EN, Kathuria N, Makurumidze G, Curatola A, et al
    CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.
    Vaccine. 2020 Feb 10. pii: S0264-410X(20)30038.
    >> Share

  57. MADHI SA, Moreira M, Koen A, van Niekerk N, et al
    Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.
    Vaccine. 2020 Feb 5. pii: S0264-410X(20)30100.
    >> Share

    January 2020
  58. LIU J, Clayton K, Gao W, Li Y, et al
    Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice.
    Vaccine. 2020 Jan 31. pii: S0264-410X(20)30076.
    >> Share

  59. SALAMI K, Gsell PS, Olayinka A, Maiga D, et al
    Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10-11 September 2019.
    Vaccine. 2020 Jan 14. pii: S0264-410X(20)30032.
    >> Share

  60. MA P, Luo Z, Qian J, Yan Z, et al
    Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.
    Vaccine. 2020 Jan 13. pii: S0264-410X(20)30004.
    >> Share

  61. VAN DER MEEREN O, Jongert E, Seaton KE, Koutsoukos M, et al
    Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31722.
    >> Share

  62. PUENTE-MASSAGUER E, Lecina M, Godia F
    Application of advanced quantification techniques in nanoparticle-based vaccine development with the Sf9 cell baculovirus expression system.
    Vaccine. 2020 Jan 3. pii: S0264-410X(19)31647.
    >> Share

    December 2019
  63. LUTZ CS, Fink RV, Cloud AJ, Stevenson J, et al
    Factors associated with perceptions of influenza vaccine safety and effectiveness among adults, United States, 2017-2018.
    Vaccine. 2019 Dec 27. pii: S0264-410X(19)31644.
    >> Share

  64. OLWAGEN CP, Adrian PV, Madhi SA
    Evaluation of the impact of HIV-1 infection and density of common nasopharyngeal bacterial colonizers in South African children immunized with 7-valent pneumococcal conjugate vaccine.
    Vaccine. 2019 Dec 21. pii: S0264-410X(19)31675.
    >> Share

  65. VILLAGOMEZ AN, Munoz FM, Peterson RL, Colbert AM, et al
    Neurodevelopmental delay: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2019;37:7623-7641.
    >> Share

    November 2019
  66. REINDERS S, Romero C, Carcamo C, Tinoco Y, et al
    A community-based survey on influenza and vaccination knowledge, perceptions and practices in Peru.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31539.
    >> Share

  67. FOUDA GG, De Paris K, Levy O, Marchant A, et al
    Immunological mechanisms of inducing HIV immunity in infants.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31518.
    >> Share

  68. D'SOUZA MP, Rele S, Haynes BF, Hu DJ, et al
    Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology.
    Vaccine. 2019 Nov 20. pii: S0264-410X(19)31409.
    >> Share

  69. STEIGERWALD R, Brake DA, Barrera J, Schutta CJ, et al
    Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle.
    Vaccine. 2019 Nov 9. pii: S0264-410X(19)31505.
    >> Share

  70. OTIENO L, Guerra Mendoza Y, Adjei S, Agbenyega T, et al
    Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31466.
    >> Share

    October 2019
  71. SUN W, Li Q, Ning X, Yang Y, et al
    TFPR1 acts as an immune regulator and an efficient adjuvant for proteins and peptides by activating immune cells, primarily through TLR2.
    Vaccine. 2019 Oct 16. pii: S0264-410X(19)31380.
    >> Share

  72. BERNSTEIN DI, Morello CS, Cardin RD, Bravo FJ, et al
    A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
    Vaccine. 2019 Oct 11. pii: S0264-410X(19)31332.
    >> Share

    September 2019
  73. KAUFFMANN F, Van Damme P, Leroux-Roels G, Vandermeulen C, et al
    Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework.
    Vaccine. 2019;37:6144-6153.
    >> Share

  74. BIGGERSTAFF M, Cohen C, Reed C, Tempia S, et al
    A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.
    Vaccine. 2019 Sep 28. pii: S0264-410X(19)31283.
    >> Share

  75. FU M, Hu K, Hu H, Ni F, et al
    Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Vaccine. 2019 Sep 26. pii: S0264-410X(19)31301.
    >> Share

  76. MARUYAMA J, Mateer EJ, Manning JT, Sattler R, et al
    Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
    Vaccine. 2019 Sep 24. pii: S0264-410X(19)31230.
    >> Share

  77. KUMRU OS, Saleh-Birdjandi S, Antunez LR, Sayeed E, et al
    Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
    Vaccine. 2019 Sep 20. pii: S0264-410X(19)31227.
    >> Share

  78. CONNOCHIE D, Tingler RC, Bauermeister JA
    Young men who have sex with men's awareness, acceptability, and willingness to participate in HIV vaccine trials: Results from a nationwide online pilot study.
    Vaccine. 2019 Sep 13. pii: S0264-410X(19)31152.
    >> Share

  79. SAKURAI A, Ogawa T, Matsumoto J, Kihira T, et al
    Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan.
    Vaccine. 2019 Sep 7. pii: S0264-410X(19)31095.
    >> Share

    August 2019
  80. DORAIVELU K, Boulet SL, Biswas HH, Adams JC, et al
    Predictors of tetanus, diphtheria, acellular pertussis and influenza vaccination during pregnancy among full-term deliveries in a medically underserved population.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31108.
    >> Share

  81. BEUN AJ, Grammens T, Hainaut M, Barlow P, et al
    High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study.
    Vaccine. 2019 Aug 23. pii: S0264-410X(19)31098.
    >> Share

  82. PRIVATT SR, Bullard BL, Weaver EA, Wood C, et al
    Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.
    Vaccine. 2019 Aug 1. pii: S0264-410X(19)30995.
    >> Share

    July 2019
  83. JANEWONGWIROT P, Jantarabenjakul W, Anugulruengkitt S, Anunsittichai O, et al
    A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30953.
    >> Share

  84. VENEREO-SANCHEZ A, Fulton K, Koczka K, Twine S, et al
    Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30955.
    >> Share

  85. GIDUDU JF, Shaum A, Habersaat K, Wilhelm E, et al
    An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration.
    Vaccine. 2019 Jul 20. pii: S0264-410X(19)30932.
    >> Share

  86. SIMOES EAF, Nunes MC, Carosone-Link P, Madimabe R, et al
    Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes.
    Vaccine. 2019 Jul 19. pii: S0264-410X(19)30915.
    >> Share

  87. BRIDGES CB, Watson TL, Nelson NP, Chavez-Torres M, et al
    Challenges with hepatitis B vaccination of high risk adults - A pilot program.
    Vaccine. 2019 Jul 11. pii: S0264-410X(19)30746.
    >> Share

  88. PEREIRA AGUILAR P, Schneider TA, Wetter V, Maresch D, et al
    Polymer-grafted chromatography media for the purification of enveloped virus-like particles, exemplified with HIV-1 gag VLP.
    Vaccine. 2019 Jul 9. pii: S0264-410X(19)30878.
    >> Share

    June 2019
  89. NAYYAR A, Privor-Dumm L
    Cholera control and prevention: Role of evidence-based advocacy and communications.
    Vaccine. 2019 Jun 28. pii: S0264-410X(19)30804.
    >> Share

  90. LOH FK, Nathan S, Chow SC, Fang CM, et al
    Vaccination challenges and strategies against long-lived Toxoplasma gondii.
    Vaccine. 2019 Jun 8. pii: S0264-410X(19)30730.
    >> Share

  91. ANDRASIK M, Grove D, Broder G, Scott H, et al
    A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru.
    Vaccine. 2019 Jun 5. pii: S0264-410X(19)30630.
    >> Share

    May 2019
  92. CAWLFIELD A, Genito CJ, Beck Z, Bergmann-Leitner ES, et al
    Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Vaccine. 2019 May 28. pii: S0264-410X(19)30696.
    >> Share

  93. GOLDSTEIN ND, LeVasseur MT, Tran NK, Purtle J, et al
    Modeling HPV vaccination scale-up among urban young men who have sex with men in the context of HIV.
    Vaccine. 2019 May 25. pii: S0264-410X(19)30671.
    >> Share

  94. LIANG B, Li H, Li L, Omange RW, et al
    Current advances in HIV vaccine preclinical studies using Macaque models.
    Vaccine. 2019 May 11. pii: S0264-410X(19)30603.
    >> Share

  95. HECHTER RC, Qian L, Tartof SY, Sy LS, et al
    Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.
    Vaccine. 2019 May 4. pii: S0264-410X(19)30568.
    >> Share

  96. YANG G, Schneck NA, Barefoot N, Yang Y, et al
    Titer measurement of HIV-1 envelope trimeric glycoprotein in cell culture media by a new tandem ion exchange and size exclusion chromatography (IEC-SEC) method.
    Vaccine. 2019 May 3. pii: S0264-410X(19)30577.
    >> Share

    April 2019
  97. BOILESEN DR, Ragonnaud E, Laursen H, Andersson AC, et al
    CD8+ T cells induced by adenovirus-vectored vaccine are capable of preventing establishment of latent murine gamma-herpesvirus 68 infection.
    Vaccine. 2019 Apr 18. pii: S0264-410X(19)30485.
    >> Share

  98. NEUKAM K, Gutierrez-Valencia A, Llaves-Flores S, Espinosa N, et al
    Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions.
    Vaccine. 2019 Apr 10. pii: S0264-410X(19)30351.
    >> Share

  99. SHAPIRO SZ
    Lessons for general vaccinology research from attempts to develop an HIV vaccine.
    Vaccine. 2019 Apr 9. pii: S0264-410X(19)30442.
    >> Share

    March 2019
  100. PINTO LA, Wilkin TJ, Kemp TJ, Abrahamsen M, et al
    Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.
    Vaccine. 2019 Mar 30. pii: S0264-410X(19)30356.
    >> Share

  101. SARKAR S, Piepenbrink MS, Basu M, Thakar J, et al
    IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
    Vaccine. 2019 Mar 26. pii: S0264-410X(19)30378.
    >> Share

  102. BEKELE Y, Lemma M, Bobosha K, Yibeltal D, et al
    Homing defects of B cells in HIV-1 infected children impair vaccination responses.
    Vaccine. 2019 Mar 23. pii: S0264-410X(19)30349.
    >> Share

  103. SELINGER C, Bershteyn A, Dimitrov DT, Adamson BJS, et al
    Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30291.
    >> Share

  104. FRITZSCHE C, Bergmann L, Loebermann M, Glass A, et al
    Immune response to hepatitis A vaccine in patients with HIV.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30271.
    >> Share

  105. ABAASA A, Nash S, Mayanja Y, Price M, et al
    Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda.
    Vaccine. 2019 Mar 8. pii: S0264-410X(19)30289.
    >> Share

  106. VERELST F, Kessels R, Delva W, Beutels P, et al
    Drivers of vaccine decision-making in South Africa: A discrete choice experiment.
    Vaccine. 2019 Mar 8. pii: S0264-410X(19)30263.
    >> Share

    February 2019
  107. HAPPE M, Samuvel DJ, Ohtola JA, Korte JE, et al
    Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.
    Vaccine. 2019 Feb 20. pii: S0264-410X(19)30182.
    >> Share

  108. LI T, Zhang Z, Zhang Z, Qiao J, et al
    Characterization of native-like HIV-1 gp140 glycoprotein expressed in insect cells.
    Vaccine. 2019 Feb 5. pii: S0264-410X(19)30124.
    >> Share

    January 2019
  109. WORLD HEALTH ORGANIZATION
    Measles vaccines: WHO position paper, April 2017 - Recommendations.
    Vaccine. 2019;37:219-222.
    >> Share

    December 2018
  110. LAKHAL-NAOUAR I, Koles N, Rao M, Morrison EB, et al
    Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Vaccine. 2018 Dec 5. pii: S0264-410X(18)31577.
    >> Share

  111. LEIDNER AJ, Murthy N, Chesson HW, Biggerstaff M, et al
    Cost-effectiveness of adult vaccinations: A systematic review.
    Vaccine. 2018 Dec 4. pii: S0264-410X(18)31581.
    >> Share

    November 2018
  112. KOCHHAR S, Excler JL, Bok K, Gurwith M, et al
    Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.
    Vaccine. 2018 Nov 26. pii: S0264-410X(18)31235.
    >> Share

  113. MCMORROW ML, Tempia S, Walaza S, Treurnicht FK, et al
    Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31573.
    >> Share

  114. HURLEY LP, Allison MA, Dooling KL, O'Leary ST, et al
    Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
    Vaccine. 2018;36:7408-7414.
    >> Share

  115. NAKIBONEKA R, Mugaba S, Auma BO, Kintu C, et al
    Interferon gamma (IFN-gamma) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.
    Vaccine. 2018 Nov 17. pii: S0264-410X(18)31547.
    >> Share

    October 2018
  116. JI Y, Han X, Tian W, Gao Y, et al
    V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies.
    Vaccine. 2018 Oct 30. pii: S0264-410X(18)31471.
    >> Share

  117. HADDISON EC, Ngono D, Kouamen GT, Kagina BM, et al
    Successful polio supplementary immunisation activities in a security compromised zone - Experiences from the Southwest region of Cameroon.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31356.
    >> Share

  118. MUGO NR, Eckert L, Magaret AS, Cheng A, et al
    Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Vaccine. 2018 Oct 5. pii: S0264-410X(18)31328.
    >> Share

    September 2018
  119. PURWAR M, Pokorski JK, Singh P, Bhattacharyya S, et al
    Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles.
    Vaccine. 2018 Sep 14. pii: S0264-410X(18)31001.
    >> Share

  120. DENDLE C, Stuart RL, Mulley WR, Holdsworth SR, et al
    Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence.
    Vaccine. 2018 Sep 11. pii: S0264-410X(18)31209.
    >> Share

  121. ELBAHNASAWY MA, Donius LR, Reinherz EL, Kim M, et al
    Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses.
    Vaccine. 2018 Sep 6. pii: S0264-410X(18)31123.
    >> Share

    August 2018
  122. DAMJANOVIC D, He L, Symes J, Gajewska B, et al
    In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine.
    Vaccine. 2018 Aug 10. pii: S0264-410X(18)31003.
    >> Share

  123. NADARZYNSKI T, Smith H, Richardson D, Bremner S, et al
    Men who have sex with men who do not access sexual health clinics nor disclose sexual orientation are unlikely to receive the HPV vaccine in the UK.
    Vaccine. 2018;36:5065-5070.
    >> Share

  124. PATRICIA D'SOUZA M, Allen MA, Baumblatt JAG, Boggiano C, et al
    Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
    Vaccine. 2018 Aug 7. pii: S0264-410X(18)31080.
    >> Share

  125. SPINA FG, Gouvea A, Succi RCM, Calanca F, et al
    Immune response to a Tdap booster in vertically HIV-infected adolescents.
    Vaccine. 2018 Aug 4. pii: S0264-410X(18)31012.
    >> Share

  126. ITELL HL, McGuire EP, Muresan P, Cunningham CK, et al
    Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.
    Vaccine. 2018 Aug 4. pii: S0264-410X(18)31017.
    >> Share

    July 2018
  127. VIRNIK K, Nesti E, Dail C, Scanlan A, et al
    Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Vaccine. 2018 Jul 20. pii: S0264-410X(18)30940.
    >> Share

  128. APAYDIN KZ, Fontenot HB, Borba CPC, Shtasel DL, et al
    Three-dose HPV vaccine completion among sexual and gender minority young adults at a Boston community health center.
    Vaccine. 2018 Jul 5. pii: S0264-410X(18)30898.
    >> Share

    June 2018
  129. LIU W, Wong YC, Chen SMY, Tang J, et al
    DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Vaccine. 2018 Jun 28. pii: S0264-410X(18)30888.
    >> Share

  130. TAN N, Sharma M, Winer R, Galloway D, et al
    Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Vaccine. 2018 Jun 8. pii: S0264-410X(18)30197.
    >> Share

  131. CHESSON HW, Meites E, Ekwueme DU, Saraiya M, et al
    Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26years in the United States.
    Vaccine. 2018 Jun 7. pii: S0264-410X(18)30578.
    >> Share

    May 2018
  132. FLEMING JA, Baltrons R, Rowley E, Quintanilla I, et al
    Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30762.
    >> Share

  133. ZHANG W, Sun H, Atiquzzaman M, Sou J, et al
    Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30743.
    >> Share

  134. DAMILANO GD, Sued O, Ruiz MJ, Ghiglione Y, et al
    Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection.
    Vaccine. 2018 May 22. pii: S0264-410X(18)30606.
    >> Share

    April 2018
  135. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged >/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30376.
    >> Share

  136. IBARZ-PAVON AB, French N
    No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi.
    Vaccine. 2018 Apr 7. pii: S0264-410X(18)30478.
    >> Share

  137. LAPUENTE D, Ruzsics Z, Thirion C, Tenbusch M, et al
    Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30262.
    >> Share

  138. SPICKNALL IH, Looker KJ, Gottlieb SL, Chesson HW, et al
    Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Vaccine. 2018 Apr 3. pii: S0264-410X(18)30254.
    >> Share

    March 2018
  139. WORLD HEALTH ORGANIZATION
    BCG vaccine: WHO position paper, February 2018 - Recommendations.
    Vaccine. 2018 Mar 30. pii: S0264-410X(18)30345.
    >> Share

  140. HARRER T, Dinges W, Roman F
    Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials.
    Vaccine. 2018 Mar 29. pii: S0264-410X(18)30388.
    >> Share

  141. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged>/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30375.
    >> Share

  142. PANDEY RK, Ojha R, Aathmanathan VS, Krishnan M, et al
    Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection.
    Vaccine. 2018 Mar 20. pii: S0264-410X(18)30387.
    >> Share

    February 2018
  143. THIAM-DIOUF A, Metch B, Sharpe C, Mulugeta R, et al
    Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
    Vaccine. 2018;36:1235-1242.
    >> Share

  144. KOURKOUNTI S, Retsas T, Paparizos V, Tsimpidakis A, et al
    Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30192.
    >> Share

  145. NELSON NP, Yankey D, Singleton JA, Elam-Evans LD, et al
    Hepatitis A vaccination coverage among adolescents (13-17years) in the United States, 2008-2016.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30163.
    >> Share

  146. SHRIVASTAVA T, Samal S, Tyagi AK, Goswami S, et al
    Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Vaccine. 2018 Feb 8. pii: S0264-410X(18)30154.
    >> Share

    January 2018
  147. DE BOER PT, Kelso JK, Halder N, Nguyen TP, et al
    The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    Vaccine. 2018 Jan 17. pii: S0264-410X(17)31836.
    >> Share

    December 2017
  148. SERWANGA J, Ssemwanga D, Muganga M, Nakiboneka R, et al
    HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
    Vaccine. 2017 Dec 20. pii: S0264-410X(17)31718.
    >> Share

  149. SHIVE CL, Judge CJ, Clagett B, Kalayjian RC, et al
    Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
    Vaccine. 2017 Dec 15. pii: S0264-410X(17)31761.
    >> Share

  150. HIBBS BF, Miller E, Shi J, Smith K, et al
    Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.
    Vaccine. 2017 Dec 13. pii: S0264-410X(17)31726.
    >> Share

  151. HABER P, Moro PL, Ng C, Lewis PW, et al
    Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31722.
    >> Share

  152. HERBECK JT, Peebles K, Edlefsen PT, Rolland M, et al
    HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31731.
    >> Share

  153. GOTTLIEB SL, Giersing BK, Hickling J, Jones R, et al
    Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492.
    >> Share

    November 2017
  154. WENIGER BG, Anglin IE, Tong T, Pensiero M, et al
    Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31479.
    >> Share

  155. NANNI A, Meredith S, Gati S, Holm K, et al
    Strengthening global vaccine access for adolescents and adults.
    Vaccine. 2017 Nov 6. pii: S0264-410X(17)31419.
    >> Share

    October 2017
  156. FROTA ACC, Ferreira B, Harrison LH, Pereira GS, et al
    Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
    Vaccine. 2017 Oct 31. pii: S0264-410X(17)31451.
    >> Share

  157. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    >> Share

  158. SLEZAK J, Meyer K, Sy LS, Chao C, et al
    An imputation method for calculating and comparing autoimmune disease incidence using partial case review.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31418.
    >> Share

  159. IZURIETA HS, Moro PL, Chen RT
    Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?
    Vaccine. 2017 Oct 12. pii: S0264-410X(17)31365.
    >> Share

  160. WU J, Zhao C, Liu Q, Huang W, et al
    Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system.
    Vaccine. 2017 Oct 11. pii: S0264-410X(17)31371.
    >> Share

  161. ANA-SOSA-BATIZ F, Johnston APR, Hogarth PM, Wines BD, et al
    Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults.
    Vaccine. 2017 Oct 10. pii: S0264-410X(17)31315.
    >> Share

  162. SUN P, Crum-Cianflone NF, Defang G, Williams M, et al
    Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307.
    >> Share

    September 2017
  163. NONZEE NJ, Baldwin SB, Cui Y, Singhal R, et al
    Disparities in parental human papillomavirus (HPV) vaccine awareness and uptake among adolescents.
    Vaccine. 2017 Sep 26. pii: S0264-410X(17)31134.
    >> Share

  164. CHENG L, Zhang Z, Li G, Li F, et al
    Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31300.
    >> Share

  165. SCHIFFER JT, Gottlieb SL
    Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273.
    >> Share

  166. TAN S, Zhang S, Wu B, Zhao Y, et al
    Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans.
    Vaccine. 2017 Sep 13. pii: S0264-410X(17)31159.
    >> Share

  167. SUNDARAMURTHI JC, Ashokkumar M, Swaminathan S, Hanna LE, et al
    HLA based selection of epitopes offers a potential window of opportunity for vaccine design against HIV.
    Vaccine. 2017 Sep 6. pii: S0264-410X(17)31168.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016